Company intelligence / Profile preview
Sirana Pharma
München, Bayern, Germanysirana-pharma.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Sirana Pharma is developing innovative therapies for musculoskeletal disorders using a proprietary microRNA-targeting platform. The company has entered into a collaborative research agreement with Pfizer to investigate treatments for rare bone diseases. Its approach aims at substantial regenerative recovery of diseased muscle and bone tissue. Clinical results have not been disclosed publicly as of the latest available information.
- Therapeutic areas
- Rare DiseasesRheumatology
- Modalities
- microRNA (miRNA)-targeting therapeutics
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
Pfizer Inc. (collaborative research agreement on rare bone disease)
Beyond the preview
Go deeper on Sirana Pharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sirana Pharma.